系统性硬化症胃肠道症状严重程度与进展
研究纳入Leiden和Oslo队列共834例系统性硬化症患者,基线及每年采用UCLA-GIT评分评估患者报告的胃肠道症状。基线28%报告中度至重度胃肠道症状,ACA、吸烟和糖皮质激素使用增加严重程度风险,钙通道阻滞剂似乎具有保护作用;女性及ACA预测症状进展。
要点
- 系统性硬化症病程早期即可出现高胃肠道症状负担。
- 女性、吸烟与胃肠道症状负担的患病及进展风险相关。
- ACA、吸烟和糖皮质激素使用与基线胃肠道症状严重程度风险增加相关,钙通道阻滞剂似乎具有保护作用。
核心结论
- 系统性硬化症病程早期即存在高胃肠道症状负担,女性与吸烟被确定为胃肠道症状负担患病及进展的风险因素。
研究设计与样本
- 纳入来自Leiden和Oslo队列的系统性硬化症患者,基线及每年采用经验证的UCLA-GIT评分评估患者报告的胃肠道症状,并采用逻辑回归和线性混合效应模型分析。
主要发现
- 共纳入834例有基线UCLA-GIT评分的系统性硬化症患者,其中Leiden队列454例、Oslo队列380例。
- 总队列中28%在基线报告中度至重度胃肠道症状。
- 总队列中ACA、吸烟和糖皮质激素使用与基线胃肠道症状严重程度风险增加相关,钙通道阻滞剂使用似乎具有保护作用。
- 早期疾病队列中23%在基线报告中度至重度胃肠道症状,女性与吸烟与风险增加相关。
- 随时间推移症状负担主要因反流/腹胀而增加,女性及ACA预测胃肠道症状进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the severity and evolution of patient-reported gastrointestinal tract (GIT) symptoms in systemic sclerosis (SSc) patients, assess predictive factors for progression and determine the impact of standard of care treatment. METHODS: SSc patients from the Leiden and Oslo cohorts were included. We assessed clinical data and patient-reported GIT symptoms measured by the validated University of California, Los-Angeles Gastrointestinal-tract (UCLA-GIT) score at baseline and annually. GIT severity and progression was determined. Logistic regression was applied to identify risk factors associated with baseline GIT symptom severity. Linear mixed-effect models were applied to assess progression in GIT symptom burden and to identify predictive factors. We repeated all analysis in patients with early disease (inception cohort) to exclude the effect of longstanding disease and increase insights in development of GIT symptom burden early in the disease course. RESULTS: We included 834 SSc patients with baseline UCLA GIT scores, 454 from Leiden and 380 from Oslo. In the total cohort, 28% reported moderate-severe GIT symptoms at baseline, with increased risk for severity conferred by ACA, smoking and corticosteroid use, while use of calcium channel blockers appeared protective. In the inception cohort, 23% reported moderate-severe GIT symptoms at baseline, with increased risk for females and with smoking. Over time, symptom burden increased mainly for reflux/bloating. Female sex and ACA predicted GIT symptom progression. CONCLUSION: High GIT symptom burden is present early in SSc disease course. Both for prevalence and for progression of GIT symptom burden, female sex and smoking were identified as risk factors.
引用
- van Leeuwen NM, Boonstra M, Fretheim H, et al. Gastrointestinal symptom severity and progression in systemic sclerosis. Rheumatology (Oxford). 2022. PMID: 35238377. doi:10.1093/rheumatology/keac118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。